Alkermes plc is a fully-integrated global biopharmaceutical company developing innovative medicines that are designed to address unmet medical needs of patients in major therapeutic areas. Alkermes has a diversified portfolio of commercial medicines and a clinical pipeline of development candidates focused on central nervous system (CNS) disorders such as schizophrenia, depression, addiction and multiple sclerosis; and on cancer. Headquartered in Dublin, Ireland, Alkermes has a research and development (R&D) center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio.
Alkermes strives to manage its business in a manner that promotes transparent governance, strong ethics, and environmental stewardship; maintains extensive patient, employee, and other stakeholder engagement; and helps Alkermes grow its business strategically, sustainably, and responsibly, including with respect to its environmental, social, and governance (ESG) impacts.
For more information, please visit Alkermes’ website at www.alkermes.com.
Check out Alkermes Corporate Responsibility